For Tina, finally getting a diagnosis of Sjögren’s was a relief. Tina Aswani Omprakash’s hospital bedside table was crowded with an unusual collection of items she regularly used to combat dryness ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of ...

Unsere Mission Novartis ist eines der führenden Pharmaunternehmen in Österreich, durch unsere langjährige Tätigkeit in der Forschung, Entwicklung, Herstellung innovativer Medikamente zur Versorgung ...

Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with ...

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key ...

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in ...